

-28-

WHAT IS CLAIMED IS:

1. A method to provide an adjunct to the therapeutic administration of a toxin, the method comprising steps of:
providing a human-compatible antitoxin, the antitoxin corresponding to the administered toxin; intravenously injecting the antitoxin into a patient who has received the toxin.
2. The method of claim 1 wherein the administered toxin is a neurotoxin.
3. The method of claim 1 wherein the administered toxin is botulinum toxin.
4. The method of claim 1 wherein the antitoxin is botulism immune globulin.
5. The method of claim 1 wherein the antitoxin comprises antibodies to botulinum toxin type A, B, C, D, D, or E.
6. The method of claim 1 wherein the antitoxin comprises antibodies to botulinum toxin type F or G.
7. The method of claim 2 wherein the neurotoxin is *Clostridium baratii* type F-like toxin.
8. The method of claim 2 wherein the neurotoxin is *Clostridium butyricum* type E-like toxin.

-29-

9. The method of claim 1 wherein the human-derived antitoxin is produced as monoclonal or polyclonal antibodies.

5 10. The method of claim 1 wherein the administered toxin is tetanus toxin.

10 11. The method of claim 1 wherein the step of intravenously injecting the antitoxin occurs at least about two hours after the patient has received the toxin.

15 12. The method of claim 1 wherein the administered toxin is *Clostridium perfringens* kappa toxin.

20 13. The method of claim 1 wherein the administered toxin is cobra neurotoxin.

25

30

35

93299.2

-30-

14. A method for treating a patient with a neuromuscular disorder, the method comprising steps of:
administering an amount of a toxin;
providing a human-compatible antitoxin, the
5 antitoxin corresponding to the administered toxin;
intravenously administering the antitoxin to
the patient who has received the toxin.

15. The method of claim 14 wherein the toxin
10 is administered intramuscularly.

16. The method of claim 14 wherein the toxin
is a neurotoxin.

17. The method of claim 14 wherein the toxin
15 is botulinum toxin.

18. The method of claim 17 wherein between
about 0.1 and 400 treatment units of botulinum toxin are
20 administered during a treatment session.

19. The method of claim 14 wherein the
antitoxin is botulism immune globulin.

20. The method of claim 19 wherein sufficient
25 botulism immune globulin is intravenously injected to
neutralize about 10% to 90% of the injected toxin.

21. The method of claim 19 wherein between
30 about 1×10^{-6} to 3.6×10^{-2} International Units of
botulism immune globulin are administered.

22. The method of claim 19 wherein the
botulism immune globulin is administered between about 2
35 and 72 hours after the toxin is administered.

-31-

23. The method of claim 14 wherein the
administered toxin is cobra neurotoxin.

5

10

15

20

25

30

35